This is an open-label, dose escalation trial designed to assess safety and tolerability of 4 dose strengths and 1-2 cycles of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a clinical diagnosis of Metastases to the Choroid, from a histopathologically or cytologically confirmed tumor.
Have at least one Metastases to the Choroid in the study eye
You may not be if
Active ocular infection or disease.
Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment.
Must not be planning or expecting to switch/add systemic antineoplastic therapies during treatment
Clareo Health | Suprachoroidal Administration in Subjects With Metastases to the Choroid
